Novel therapies in bladder cancer

Clinical Oncology

Volumn 17, Issue 7, 2005, Pages 524-538

  Alonzi, R ^a   Hoskin, Peter ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Bladder cancer; Chemoradiation; Fractionation; Hypoxia; Protons; Radiotherapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTON AS2-1; BEVACIZUMAB; BORTEZOMIB; CANCER VACCINE; CARBOGEN; CETUXIMAB; CISPLATIN; DOXIFLURIDINE; DOXORUBICIN; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERIBITUX; ERLOTINIB; FLUOROURACIL; FR 901228; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GEMCITABINE; IMC 225; METHOTREXATE; MITOMYCIN C; NICOTINAMIDE; PACLITAXEL; PLATINUM DERIVATIVE; TIPIFARNIB; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE; VINFLUNINE;

BLADDER CANCER; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; DRUG SYNTHESIS; GENE THERAPY; HUMAN; HYDRONEPHROSIS; HYPOXIA; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; MITOGENESIS; MULTIMODALITY CANCER THERAPY; NEPHROTOXICITY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT PLANNING;

EID: 25144517088     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2005.07.001     Document Type: Article

References (98)

1. J. Simon Ectopia vesicae (absence of the anterior walls of the bladder and pubic abdominal parietes); operation for directing the orifices of the ureters into the rectum; temporary success; subsequent death; autopsy Lancet 2 1852 268-271
2. P.N. Schlegel P.C. Walsh Neuroanatomical approach to radical cystoprostatectomy with preservation of sexual function J Urol 138 1987 1402-1406
3. C.M. Hall C.P. Dinney Radical cystectomy for stage T3b bladder cancer Semin Urol Oncol 14 1996 73-80
4. F. Pagano P. Bassi T.P. Galetti et al. Results of contemporary radical cystectomy for invasive bladder cancer: A clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification J Urol 145 1991 45-50
5. D. Raghavan W.U. Shipley M.B. Garnick P.J. Russell J.P. Richie Biology and management of bladder cancer N Engl J Med 322 1990 1129-1138
6. K.I. Wishnow A.K. Levinson D.E. Johnson et al. Stage B (P2/3A/N0) transitional cell carcinoma of bladder highly curable by radical cystectomy Urology 39 1992 12-16
7. H.J. Bloom W.F. Hendry D.M. Wallace R.G. Skeet Treatment of T3 bladder cancer: Controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy Br J Urol 54 1982 136-151
8. M.K. Gospodarowicz N.V. Hawkins G.A. Rawlings et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: Failure analysis J Urol 142 1989 1448-1453 [discussion 1453-1454].
9. P.M. Quilty W. Duncan Primary radical radiotherapy for T3 transitional cell cancer of the bladder: An analysis of survival and control Int J Radiat Oncol Biol Phys 12 1986 853-860
10. H. Mameghan R. Fisher J. Mameghan S. Brook Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder Int J Radiat Oncol Biol Phys 31 1995 247-254
11. H.W. Herr Uncertainty, stage and outcome of invasive bladder cancer J Urol 152 2 Pt 1 1994 401-402
12. J. Vieweg J.E. Gschwend H.W. Herr W.R. Fair Pelvic lymph node dissection can be curative in patients with node positive bladder cancer J Urol 161 1999 449-454
13. W. De Neve M.L. Lybeert C. Goor M.A. Crommelin J.G. Ribot Radiotherapy for T2 and T3 carcinoma of the bladder: The influence of overall treatment time Radiother Oncol 36 1995 183-188
14. B.J. Jenkins M.J. Caulfield C.G. Fowler et al. Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer Br J Urol 62 1988 343-346
15. W. Duncan P.M. Quilty The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy Radiother Oncol 7 1986 299-310
16. S. Borgaonkar A. Jain P. Bollina et al. Radical radiotherapy and salvage cystectomy as the primary management of transitional cell carcinoma of the bladder. Results following the introduction of a CT planning technique Clin Oncol 14 2002 141-147
17. J. Dunst R. Sauer K.M. Schrott R. Kuhn C. Wittekind A. Altendorf-Hofmann Organ-sparing treatment of advanced bladder cancer: A 10-year experience Int J Radiat Oncol Biol Phys 30 1994 261-266
18. L.A. Kachnic W.U. Shipley P.P. Griffin et al. Combined modality treatment with selective bladder conservation for invasive bladder cancer: Long-term tolerance in the female patient Cancer J Sci Am 2 1996 79
19. W.U. Shipley D.S. Kaufman E. Zehr et al. Selective bladder preservation by combined modality protocol treatment: Long-term outcomes of 190 patients with invasive bladder cancer Urology 60 2002 62-67 [discussion 67-68].
20. L.S. Miller Bladder cancer: Superiority of preoperative irradiation and cystectomy in clinical stages B2 and C Cancer 39 2 Suppl 1977 973-980
21. A. Sell A. Jakobsen B. Nerstrom B.L. Sorensen K. Steven H. Barlebo Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group Scand J Urol Nephrol Suppl 138 1991 193-201
22. M.D. Shelley J. Barber M.D. Mason Surgery versus radiotherapy for muscle invasive bladder cancer The Cochrane Library Issue 3 2001 John Wiley & Sons Chichester
23. S.L. Turner R. Swindell N. Bowl et al. Bladder movement during radiation therapy for bladder cancer: Implications for treatment planning Int J Radiat Oncol Biol Phys 39 1997 355-360
24. J. Davies C. McCarthy J. Stratford B. Porritt C. McBain P. Price Inter- and intra fraction volume changes in bladder radiotherapy: quantification using daily ultrasound imaging [abstract] Clin Oncol Suppl 2005 s21
25. D. Jaffray J. Siewerdsen J. Wong A. Martinez Flat-panel cone-beam computed tomography for image-guided radiation therapy Int J Radiat Oncol Biol Phys 53 2002 1337-1349
26. J. Overgaard Modification of hypoxia: From Gottwald Schwarz to nicotinamide. Have we learned the lesson? In: H.D. Kogelnik ed. Progress in radiology vol. 5 1995 Monduzzi Editore Bologna, Italy 469-475
27. P.J. Hoskin A. Sibtain F.M. Daley M.I. Saunders G.D. Wilson The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma Radiother Oncol 72 2004 159-168
28. P.J. Hoskin M.I. Saunders S. Dische Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: Hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide Cancer 86 1999 1322-1328
29. A. Rojas B. Vojnovic H. Johns et al. Radiosensitisation in normal tissues with oxygen, carbogen or nicotinamide: Therapeutic gain comparisons for fractionated X-ray schedules Radiother Oncol 39 1996 53-64
30. S.J. Falk R. Ward N.M. Bleehen The influence of carbogen breathing on tumour tissue oxygenation in man evaluated by computerised p02 histography Br J Cancer 66 1992 919-924
31. L. Martin E. Lartigau P. Weeger et al. Changes in the oxygenation of head and neck tumors during carbogen breathing Radiother Oncol 27 1993 123-130
32. M.E. Powell S.A. Hill M.I. Saunders P.J. Hoskin D.J. Chaplin Human tumor blood flow is enhanced by nicotinamide and carbogen breathing Cancer Res 57 1997 5261-5264
33. P.J. Hoskin M.R. Stratford M.I. Saunders D.W. Hall M.F. Dennis A. Rojas Administration of nicotinamide during chart: Pharmacokinetics, dose escalation, and clinical toxicity Int J Radiat Oncol Biol Phys 32 1995 1111-1119
34. P.J. Hoskin A.M. Rojas H. Phillips M.I. Saunders Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide Cancer 103 2005 2286-2297
35. J. Overgaard Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors Oncol Res 6 1994 509-518
36. C. Kirkove F. Richard P.J. Van Cangh G. Ledent M. Octave-Prignot A. Wambersie Neutron therapy of bladder carcinoma: Can a high rate of severe complications be avoided in neutron therapy? Eur Urol 24 1993 52-57
37. W. Duncan S.J. Arnott W.J. Jack et al. A report of a randomized trial of d(15)+Be neutrons compared with megavoltage X ray therapy of bladder cancer Int J Radiat Oncol Biol Phys 11 1985 2043-2049
38. R.S. Pointon G. Read D. Greene A randomised comparison of photons and 15 MeV neutrons for the treatment of carcinoma of the bladder Br J Radiol 58 1985 219-224
39. G.E. Laramore R.B. Davis D.H. Hussey et al. Radiation Therapy Oncology Group Phase I-II study on fast neutron teletherapy for carcinoma of the bladder Cancer 54 1984 432-439
40. J.J. Battermann Results of d + T fast neutron irradiation on advanced tumors of bladder and rectum Int J Radiat Oncol Biol Phys 8 1982 2159-2164
41. R. Miralbell Conformational radiotherapy for bladder cancer: Limits to precision and potential advantages of the utilization of proton beams Arch Esp Urol 52 1999 684-691 [in Spanish].
42. H. Tsujii H. Tsuji T. Inada et al. Clinical results of fractionated proton therapy Int J Radiat Oncol Biol Phys 25 1993 49-60
43. N. Miyanaga Y. Ami M. Ohtani et al. Clinical study of proton radiotherapy in urological cancers Nippon Hinyokika Gakkai Zasshi 81 1990 251-257 [in Japanese].
44. U.E. Studer E. Gerber A. Zimmermann R. Kraft C.F. von Essen Late results in patients treated with pi-mesons for bladder cancer Cancer 71 1993 439-447
45. B. Maciejewski S. Majewski Dose fractionation and tumour repopulation in radiotherapy for bladder cancer Radiother Oncol 21 1991 163-170
46. W. Majewski B. Maciejewski S. Majewski R. Suwinski L. Miszczyk R. Tarnawski Clinical radiobiology of stage T2-T3 bladder cancer Int J Radiat Oncol Biol Phys 60 2004 60-70
47. L. Moonen H. vd Voet R. de Nijs A.A. Hart S. Horenblas H. Bartelink Muscle-invasive bladder cancer treated with external beam radiotherapy: pretreatment prognostic factors and the predictive value of cystoscopic re-evaluation during treatment Radiother Oncol 49 1998 149-155
48. J.D. Cox C. Guse S. Asbell P. Rubin W.T. Sause Tolerance of pelvic normal tissues to hyperfractionated radiation therapy: Results of Protocol 83-08 of the Radiation Therapy Oncology Group Int J Radiat Oncol Biol Phys 15 1988 1331-1336
49. D.J. Cole K.R. Durrant J.T. Roberts P.J. Dawes H. Yosef J.W. Hopewell A pilot study of accelerated fractionation in the radiotherapy of invasive carcinoma of the bladder Br J Radiol 65 1992 792-798
50. L. Moonen H. van der Voet S. Horenblas H. Bartelink A feasibility study of accelerated fractionation in radiotherapy of carcinoma of the urinary bladder Int J Radiat Oncol Biol Phys 37 1997 537-542
51. A.A. Yavuz M.N. Yavuz G.K. Ozgur et al. Accelerated superfractionated radiotherapy with concomitant boost for invasive bladder cancer Int J Radiat Oncol Biol Phys 56 2003 734-745
52. A. Horwich D. Dearnaley R. Huddart et al. A randomised trial of accelerated radiotherapy for localised invasive bladder cancer Radiother Oncol 75 2005 34-43
53. F. Edsmyr L. Andersson P.L. Esposti B. Littbrand B. Nilsson Irradiation therapy with multiple small fractions per day in urinary bladder cancer Radiother Oncol 4 1985 197-203
54. A.N. Scholten J.W. Leer C.D. Collins J. Wondergem J. Hermans A. Timothy Hypofractionated radiotherapy for invasive bladder cancer Radiother Oncol 4 1997 163-169
55. R. Morrison The results of treatment of cancer of the bladder-a clinical contribution to radiobiology Clin Radiol 26 1975 67-75
56. B. van der Werf-Messing Telecobalt treatment of carcinoma of the bladder Clin Radiol 16 1965 165-172
57. D.J. Brenner E.J. Hall Fractionation and protraction for radiotherapy of prostate carcinoma Int J Radiat Oncol Biol Phys 43 1999 1095-1101
58. J. Fowler R. Chappell M. Ritter Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50 2001 1021-1031
59. S.W. Walbom-Jorgensen Treatment of bladder carcinoma with 6 MeV linear accelerator Scand J Urol Nephrol 6 Suppl 15 1972 113-119
60. R. Finney Treatment of carcinoma of the bladder by external irradiation - a clinical trial part III Clin Radiol 31 1980 423-425
61. G.B. Goodman T.G. Hislop J.M. Elwood J. Balfour Conservation of bladder function in patients with invasive bladder cancer treated by definitive irradiation and selective cystectomy Int J Radiat Oncol Biol Phys 7 1981 569-573
62. R.P. Abratt R.D. Tucker D.R. Barnes Radical irradiation of T2 grade III and T3 bladder cancer-tumor response and prognosis Int J Radiat Oncol Biol Phys 9 1983 1213-1215
63. H. Mameghan R.J. Fisher W.H. Watt et al. The management of invasive transitional cell carcinoma of the bladder. Results of definitive and preoperative radiation therapy in 390 patients treated at the Prince of Wales Hospital, Sydney, Australia Cancer 69 1992 2771-2778
64. S.D. Fossa H. Waehre N. Aass A.B. Jacobsen D.R. Olsen S. Ous Bladder cancer definitive radiation therapy of muscle-invasive bladder cancer. A retrospective analysis of 317 patients Cancer 72 1993 3036-3043
65. B. Sherwood G. Jones J. Mellon R. Kockelbergh W. Steward R. Symonds Concomitant chemoradiotherapy for muscle-invasive bladder cancer: The way forward for bladder preservation? Clin Oncol 17 2005 160-166
66. G. Jakse H. Frommhold D. zur Nedden Combined radiation and chemotherapy for locally advanced transitional cell carcinoma of the urinary bladder Cancer 55 1985 1659-1664
67. C.M. Coppin E. Brown Concurrent cisplatin with radiation for locally advanced bladder cancer: A pilot study suggesting improved survival [abstract] Proc Am Soc Clin Oncol 5 1986 99
68. W.U. Shipley G.R. Prout Jr. A.B. Einstein et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery JAMA 258 1987 931-935
69. M. Rotman R. Macchia M. Silverstein et al. Treatment of advanced bladder carcinoma with irradiation and concomitant 5-fluorouracil infusion Cancer 59 1987 710-714
70. K.J. Russell M.A. Boileau C. Higano et al. Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder Int J Radiat Oncol Biol Phys 19 1990 693-699
71. J. Rebischung J. Vannetzel F. Fournier P. Larrouturou J. Brisset Cyclic concomitant chemoradiotherapy (CCCR) for invasive bladder cancer: Phase 2 study with organ preservation [abstract] Proc Am Soc Clin Oncol 11 1992 208
72. W. Tester A. Porter S. Asbell et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-12 Int J Radiat Oncol Biol Phys 25 1993 783-790
73. M. Orsatti A. Curotto L. Canobbio et al. Alternating chemo-radiotherapy in bladder cancer: A conservative approach Int J Radiat Oncol Biol Phys 33 1995 173-178
74. W. Tester R. Caplan J. Heaney et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802 J Clin Oncol 14 1996 119-126
75. C.M. Coppin M.K. Gospodarowicz K. James et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 14 1996 2901-2907
76. M. Housset B. Dufour C. Maulard-Durdux Y. Chretien A. Mejean Concomitant fluorouracil (5-FU)-cisplatin (CDDP) and bifractionated split course radiation therapy (BSCRT) for invasive bladder cancer [abstract] Proc Am Soc Clin Oncol 16 1997 319
77. W.U. Shipley K.A. Winter D.S. Kaufman et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03 J Clin Oncol 16 1998 3576-3583
78. F. Arias M.A. Dominguez E. Martinez et al. Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program Int J Radiat Oncol Biol Phys 47 2000 373-378
79. D.S. Kaufman K.A. Winter W.U. Shipley et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: Phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response Oncologist 5 2000 471-476
80. M.H. Hussain T.R. Glass J. Forman et al. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: A Southwest Oncology Group Study J Urol 165 2001 56-60 [discussion 60-61].
81. C. Rodel G.G. Grabenbauer R. Kuhn et al. Organ preservation in patients with invasive bladder cancer: Initial results of an intensified protocol of transurethral surgery and radiation therapy plus concurrent cisplatin and 5-fluorouracil Int J Radiat Oncol Biol Phys 52 2002 1303-1309
82. C. Rodel G.G. Grabenbauer R. Kuhn et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results J Clin Oncol 20 2002 3061-3071
83. W.C. Chen C.C. Liaw C.K. Chuang et al. Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer Int J Radiat Oncol Biol Phys 56 2003 726-733
84. M.P. Hagan K.A. Winter D.S. Kaufman et al. RTOG 97-06: Initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy Int J Radiat Oncol Biol Phys 57 2003 665-672
85. M. Peyromaure J. Slama P. Beuzeboc D. Ponvert B. Debre M. Zerbib Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution Urology 63 2004 73-77
86. S.A. Hussain D.D. Stocken D.R. Peake et al. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer Br J Cancer 90 2004 2106-2111
87. D.S. Kaufman W. Stadler M. Carducci Gemcitabine (Gem) plus cisplatin (CDDP) in metastatic transitional cell carcinoma (TCC): Final results of a phase II study [abstract] Proc Am Soc Clin Oncol 17 1998 320
88. M.J. Moore E.W. Winquist N. Murray et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 17 1999 2876-2881
89. P. Burch R. Richardson S. Cha Combination paclitaxel and cisplatin is active in advanced urothelial carcinoma (UC) [abstract] Proc Am Soc Clin Oncol 16 1997 329
90. R. Dreicer B. Roth S. Lipsitz Cisplatin and paclitaxel in advanced carcinoma of the urothelium: A Phase II trial of the Eastern Cooperative Oncology Group (ECOG) [abstract 1233] Proc Am Soc Clin Oncol 17 1998 320
91. B. Murphy D. Johnson J. Smith Phase II trial of paclitaxel (P) and cisplatin (C) for metastatic or locally unresectable urothelial cancer [abstract 617] Proc Am Soc Clin Oncol 15 1996 245
92. N.H. Chow S.H. Chan T.S. Tzai C.L. Ho H.S. Liu Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder Clin Cancer Res 7 2001 1957-1962
93. K. Inoue J.W. Slaton P. Perrotte et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma Clin Cancer Res 6 2000 4874-4884
94. P. Perrotte T. Matsumoto K. Inoue et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice Clin Cancer Res 5 1999 257-265
95. Z. Du S. Hou The anti-angiogenic activity of human endostatin inhibits bladder cancer growth and its mechanism J Urol 170 2003 2000-2003
96. K. Inoue M. Chikazawa S. Fukata C. Yoshikawa T. Shuin Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder Clin Cancer Res 8 2002 2389-2398
97. Z. Latif A.D. Watters I. Dunn K. Grigor M.A. Underwood J.M. Bartlett HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: A role for anti-HER2 therapy? Eur J Cancer 40 2004 56-63
98. L.C. Pagliaro Gene therapy for bladder cancer World J Urol 18 2000 148-151